Mitophagy and Autophagy in Elderly Subjects

Aging Clinical Trial

Official title:

Assessment and Reproducibility of Mitochondrial Function and Mitophagy Measurements in Human Muscle Tissue of Active and Pre Frail Elderly Males

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02472340
• Other study ID #: CHDR1510
• Secondary ID: 15.01.AMZ
• Status: Completed
• Phase: N/A
• First received: June 9, 2015
• Last updated: July 29, 2016
• Start date: June 2015
• Est. completion date: July 2016

Study information

• Verified date: March 2016
• Source: Amazentis SA
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Observational

Clinical Trial Summary

In recent years, evidence has shown that mitochondrial dysfunction plays an important role in the development of age-related muscle decline that may lead to frailty.

During aging, there is a progressive reduction in the cell's capacity to eliminate its dysfunctional elements by autophagy, as evidenced by the accumulation of oxidative damage and mutations in mitochondria and by the decrease in autophagic flux. In fact, it has been demonstrated that dysfunctional mitochondria can be specifically targeted for elimination by autophagy, a process that has been termed mitophagy.

A major challenge in the clinic today is in the lack of validated tools, including biomarkers, to assess the decline in mitochondrial health associated with an impairment in muscle function. In the present study, the investigators will employ a battery of established and exploratory tests (clinical, physiological and molecular) to assess in vivo mitochondrial function and more specifically, the levels of mitophagy and autophagy, in the muscle of healthy and pre-frail elderly.

It is anticipated that the results of this study will facilitate the rapid translation of interventions targeting mitophagy and autophagy for the improvement of muscle function.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: July 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 61 Years to 85 Years

Eligibility

Inclusion Criteria:

• for Active, Healthy subjects:

1. >61 years of age, inclusive.

2. Healthy male subjects. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, haematology, blood chemistry, and urinalysis.

3. Body mass index (BMI) between 15 and 32 kg/m2, inclusive.

4. Able to participate and willing to give written informed consent and to comply with the study restrictions.

5. Category 2 or 3 as assessed by the International Physical Activity Questionnaires (IPAQ). Activity level is = 600 MET (metabolic equivalent unit) - minutes per week.

6. Normal physical performance: normal gait speed, i.e. a walking = 0.8 m/s in the 4-m walking test.

7. Normal muscle mass: normal skeletal muscle mass index (SMI), measured by Bioimpedance analysis (BIA, = 10.75 kg/m2).

8. Normal muscle strength: handgrip strength (measured with the Jamar dynamometer) of = 30 kg.

for Sedentary, Pre-frail subjects:

1. Sedentary, pre-frail males. Pre-frailty is defined as fulfilling to at least two out of the following three criteria: low physical performance (low gait speed, i.e. a walking speed below 0.8 m/s in the 4-m walking test), low muscle mass (a low skeletal muscle mass index (SMI), measured by Bioimpedance analysis (BIA, < 10.75 kg/m2)) and/or low muscle strength: handgrip strength (measured with the Jamar dynamometer) of < 30 kg. Sedentary behaviour is defined as having an activity category of 1 as assessed by the International Physical Activity Questionnaires (IPAQ) (Activity level is = 600 MET (metabolic equivalent unit) - minutes per week).

2. Body mass index (BMI) between 15 and 32 kg/m2, inclusive.

3. Able to participate and willing to give written informed consent and to comply with the study restrictions.

4. >61 years of age, inclusive.

Exclusion Criteria:

• for Active, Healthy subjects:

1. Presence of any contraindication to have MRI scans performed (e.g. pacemaker, intracranial clips etc.).

2. Having diabetes mellitus or lower extremity peripheral vascular disease, as these conditions may interfere with interpretation of the dynamic 31P-MRS and NIRS of the lower extremity.

3. Participation in a clinical trial within 90 days of screening or more than 4 times in the previous year.

4. A history (within 3 months of screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol).

5. Smoking within 3 months prior to screening and inability to refrain from smoking during the course of the study (from screening to End-of-Study [EOS]).

6. A history or presence of allergy to 5-aminolevulinic acid or porphyrins.

7. A history or presence of allergy to lidocaine.

8. Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.

9. Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening.

10. Unwillingness or inability to refrain from consuming alcohol within 48 hours before each visit until the end of that visit.

11. Unwillingness or inability to refrain from consuming 8 or more units of xanthine containing beverages and foods per day during the entire study.

12. Unwillingness or inability to refrain from consuming the following supplements:

L-carnitine, creatine, Q10, vitamin A, niacin, folic acid, vitamin C, vitamin E and probiotic- foods and supplements at least two weeks before study enrolment.

13. Unwillingness or inability to have a muscle biopsy performed.

For Sedentary, Pre-frail subjects

1. Presence of any contraindication to have MRI scans performed (e.g. pacemaker, intracranial clips etc.).

2. Having diabetes mellitus or lower extremity peripheral vascular disease, as these conditions may interfere with interpretation of the dynamic 31P-MRS and NIRS of the lower extremity.

3. Participation in a clinical trial within 90 days of screening or more than 4 times in the previous year.

4. A history (within 3 months of screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol).

5. Smoking within 3 months prior to screening and inability to refrain from smoking during the course of the study (from screening to EOS).

6. A history or presence of allergy to 5-aminolevulinic acid or porphyrins.

7. A history or presence of allergy to lidocaine.

8. Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.

9. Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening.

10. Unwillingness or inability to refrain from consuming alcohol within 48 hours before each visit until the end of that visit.

11. Unwillingness or inability to refrain from consuming 8 or more units of xanthine containing beverages and foods per day during the entire study.

12. Unwillingness or inability to refrain from consuming the following supplements:

L-carnitine, creatine, Q10, vitamin A, niacin, folic acid, vitamin C, vitamin E and probiotic- foods and supplements at least two weeks before study enrolment.

13. Unwillingness or inability to have a muscle biopsy performed.

14. Underlying chronic disease, which, in the opinion of the investigator would interfere with study participation or the validity of the measurements.

15. Unintentional weight loss =5% of usual body weight during the last 6 months.

16. Anorexia or anorexia-related symptoms

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Aging
• Frailty
• Mitophagy

Intervention

Procedure:
• Muscle Biopsy
Muscle Biopsy

Locations

Country	Name	City	State
Netherlands	Centre for Human Drug Research	Leiden

Sponsors (2)

Lead Sponsor	Collaborator
Amazentis SA	Centre for Human Drug Research, Netherlands

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Ratio of mtDNA to nuDNA in muscle		9 months	No
Other	Gene and protein expression for mitophagy and autophagy in PBMC's		9 months	No
Other	Skeletal muscle subtype via histology		9 months	No
Primary	Gene and protein expression for autophagy and mitophagy biomarkers in muscle tissue		9 months	No
Secondary	PCr recovery time (in seconds) measured by 31P-MRS (31-Phosphorus Magnetic Resonance Spectroscopy).		9 months	No
Secondary	mVO2 (in ml/min/100 ml) in muscle measured by NIRS (Near-infrared Spectroscopy)		9 months	No
Secondary	MitoPO2 (in mmHg) in the skin measured by PpIX-TSLT (Protoporphyrin IX - Triplet State Lifetime Technique).		9 months	No
Secondary	Hand grip strength (in kg) measured by the Jamar dynamometer.		9 months	No
Secondary	Peak muscle force of quadriceps measured by handheld dynamometry		9 months	No
Secondary	Postural stability (in mm sway) measured by body sway		9 months	No
Secondary	Level of activity, using the Vital Connect HealthPatch accelerometer		9 months	No
Secondary	Short physical performance battery (SPPB) test.		9 months	No